BioCentury | Feb 8, 2020
Product Development

Coronavirus biology: where products in clinical testing intervene

The 13 therapies in clinical trials to treat coronavirus map to at least half a dozen mechanisms, intervening at three different steps in the viral cycle or manipulating different aspects of the host immune response....
BioCentury | Feb 4, 2020
Product Development

The Coronavirus outbreak: Letter from the Editor

The outbreak of the Coronavirus 2019-nCoV has caused us all to stop in our tracks, take stock of what we’re doing and what we should be doing, and reassess the plans we set out for...
BC Extra | Jan 31, 2020
Clinical News

A dozen vaccine programs under way as WHO declares coronavirus public health emergency

WHO declared the coronavirus outbreak a Public Health Emergency of International Concern Thursday and called for China and countries around the world to take public health steps to contain the virus. WHO also stressed the...
BC Extra | Jan 30, 2020
Company News

China guidelines point to HIV protease inhibitors as potential coronavirus treatment

Ascletis is seeking the approval of China’s NMPA for emergency use of its protease inhibitors to treat 2019-nCoV coronavirus after the government released guidelines suggesting AbbVie’s Kaletra as a treatment for the virus. In a...
BC Extra | Dec 11, 2019
Financial News

Local demand high for Alphamab Oncology’s Hong Kong IPO

Local investors secured additional shares as Alphamab Oncology Ltd. (HKEX:9966) priced its IPO on the Hong Kong stock exchange Wednesday in a deal that raised HK$1.8 billion ($233.8 million) and valued the company at HK$9.1...
BC Extra | Oct 8, 2019
Company News

Management tracks: BioMarin's first chief scientific strategy officer; plus Ascletis, Grail, Aerie and more

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) promoted Lon Cardon to the newly created role of chief scientific strategy officer from CSO. Prior to BioMarin, Cardon was SVP of alternative discovery and development and head of target sciences...
BC Extra | Oct 1, 2019
Company News

Management tracks: Vertex taps Bozic as CMO; plus Nektar, Sangamo, Ascletis, Neurocrine, Neovacs, Dyne, Avidity, Pulmotect, Adaptimmune and 4BIO

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said SVP and Head of Global Clinical Development Carmen Bozic will become EVP, global medicines development and medical affairs. She will take on the additional role of CMO on April 1...
BioCentury | Aug 16, 2019
Finance

Chinese investment in U.S. biotechs to slow further

Chinese VCs say the slowing of investments into U.S. biotechs is likely to get worse before it gets better. In addition to continued CFIUS concerns and the ongoing trade war, capital inflows to Chinese life...
BioCentury | Aug 12, 2019
Finance

Chipscreen sets high standard in Shanghai debut

Chipscreen became the first biopharma to begin trading on Shanghai’s STAR market this week, and the strength of its debut could entice companies sitting on the sidelines to choose a mainland listing over one in...
BC Extra | Aug 5, 2019
Financial News

Aug. 5 Financial Quick Takes: Biotech tumbles with broader markets; plus Exo, 3-V and more

Biotech stocks take a hit  U.S. biotech stocks fell in line with the broader markets Monday, with the NASDAQ Composite, NYSE Arca Biotechnology Index (BTK), SPDR S&P Biotech ETF (XBI) and BioCentury 100 each losing...
Items per page:
1 - 10 of 140
BioCentury | Feb 8, 2020
Product Development

Coronavirus biology: where products in clinical testing intervene

The 13 therapies in clinical trials to treat coronavirus map to at least half a dozen mechanisms, intervening at three different steps in the viral cycle or manipulating different aspects of the host immune response....
BioCentury | Feb 4, 2020
Product Development

The Coronavirus outbreak: Letter from the Editor

The outbreak of the Coronavirus 2019-nCoV has caused us all to stop in our tracks, take stock of what we’re doing and what we should be doing, and reassess the plans we set out for...
BC Extra | Jan 31, 2020
Clinical News

A dozen vaccine programs under way as WHO declares coronavirus public health emergency

WHO declared the coronavirus outbreak a Public Health Emergency of International Concern Thursday and called for China and countries around the world to take public health steps to contain the virus. WHO also stressed the...
BC Extra | Jan 30, 2020
Company News

China guidelines point to HIV protease inhibitors as potential coronavirus treatment

Ascletis is seeking the approval of China’s NMPA for emergency use of its protease inhibitors to treat 2019-nCoV coronavirus after the government released guidelines suggesting AbbVie’s Kaletra as a treatment for the virus. In a...
BC Extra | Dec 11, 2019
Financial News

Local demand high for Alphamab Oncology’s Hong Kong IPO

Local investors secured additional shares as Alphamab Oncology Ltd. (HKEX:9966) priced its IPO on the Hong Kong stock exchange Wednesday in a deal that raised HK$1.8 billion ($233.8 million) and valued the company at HK$9.1...
BC Extra | Oct 8, 2019
Company News

Management tracks: BioMarin's first chief scientific strategy officer; plus Ascletis, Grail, Aerie and more

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) promoted Lon Cardon to the newly created role of chief scientific strategy officer from CSO. Prior to BioMarin, Cardon was SVP of alternative discovery and development and head of target sciences...
BC Extra | Oct 1, 2019
Company News

Management tracks: Vertex taps Bozic as CMO; plus Nektar, Sangamo, Ascletis, Neurocrine, Neovacs, Dyne, Avidity, Pulmotect, Adaptimmune and 4BIO

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said SVP and Head of Global Clinical Development Carmen Bozic will become EVP, global medicines development and medical affairs. She will take on the additional role of CMO on April 1...
BioCentury | Aug 16, 2019
Finance

Chinese investment in U.S. biotechs to slow further

Chinese VCs say the slowing of investments into U.S. biotechs is likely to get worse before it gets better. In addition to continued CFIUS concerns and the ongoing trade war, capital inflows to Chinese life...
BioCentury | Aug 12, 2019
Finance

Chipscreen sets high standard in Shanghai debut

Chipscreen became the first biopharma to begin trading on Shanghai’s STAR market this week, and the strength of its debut could entice companies sitting on the sidelines to choose a mainland listing over one in...
BC Extra | Aug 5, 2019
Financial News

Aug. 5 Financial Quick Takes: Biotech tumbles with broader markets; plus Exo, 3-V and more

Biotech stocks take a hit  U.S. biotech stocks fell in line with the broader markets Monday, with the NASDAQ Composite, NYSE Arca Biotechnology Index (BTK), SPDR S&P Biotech ETF (XBI) and BioCentury 100 each losing...
Items per page:
1 - 10 of 140